{
    "clinical_study": {
        "@rank": "13513", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: ATG + CSA", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment consists of 15 mg/kg ATG (M\u00e9rieux; horse antithymocyte globulin; i.e. 1.5 vial/10 kg of body weight/day) given over 8-12 hours for 5 consecutive days.\nCyclosporine A (CSA) will be administered orally in a dose of 2.5 mg/kg bid starting day 1 and continued through day 180."
            }, 
            {
                "arm_group_label": "Arm B: Supportive care", 
                "arm_group_type": "No Intervention", 
                "description": "Patients randomized to this arm will be treated as outpatients."
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of this trial is to evaluate the efficacy and toxicity of intensive\n      immuno-suppression with ATG + CSA versus best supportive care in patients with transfusion\n      dependent low and intermediate risk myelodysplastic syndrome (MDS)."
        }, 
        "brief_title": "Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome", 
        "completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "condition": "Myelodysplastic Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This trial will answer the question whether immuno-suppression improves hematopoesis and\n      reduces transfusion requirements analogous to patients with aplastic anemia as the\n      short-term outcome, and whether immuno-suppression accelerates leukemic transformation and\n      influences survival as the long-term outcome.\n\n      Primary endpoint: best response (CR + PR) rate at month 6"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Hypoplastic MDS, or MDS subtype RA, RAS or RAEB with \u2264 10% blasts, or RAEB with 10-20%\n        blasts and the patient refusing or not eligible for the MDS high risk protocol (EORTC\n        06961)\n\n          -  Transfusion dependence < 24 months or neutrophils < 0.5 \u00d7 109/l.\n\n          -  ECOG/SAKK performance status \u2264 2\n\n          -  Age > 18 years\n\n          -  No active uncontrolled infection\n\n          -  No prior chemotherapy or radiotherapy\n\n          -  No history of heart failure, clinically relevant cardiac arrhythmia or other\n             hemato-oncological disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 21, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004208", 
            "org_study_id": "SAKK 33/99", 
            "secondary_id": "SWS-SAKK-33/99"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: ATG + CSA", 
                "description": "M\u00e9rieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)", 
                "intervention_name": "ATG + CSA", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: Supportive care", 
                "description": "Patients randomized to this arm will be treated as outpatients.", 
                "intervention_name": "Supportive care", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antilymphocyte Serum", 
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "refractory anemia", 
            "refractory anemia with ringed sideroblasts", 
            "refractory anemia with excess blasts", 
            "de novo myelodysplastic syndromes", 
            "previously treated myelodysplastic syndromes", 
            "secondary myelodysplastic syndromes"
        ], 
        "lastchanged_date": "May 14, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "zip": "CH-4031"
                }, 
                "name": "Universitaetsspital-Basel"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care", 
        "overall_official": {
            "affiliation": "Kantonsspital Basel", 
            "last_name": "Jakob R. Passweg, MS", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Best response rate (CR + PR)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "21149672", 
                "citation": "Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011 Jan 20;29(3):303-9. doi: 10.1200/JCO.2010.31.2686. Epub 2010 Dec 13."
            }, 
            {
                "citation": "Passweg JR, Giagounidis A, Simcock M, et al.: Immunosuppression for patients with low and intermediate risk myelodysplastic syndrome: a prospective randomized multicenter trial comparing antithymocyte globulin + cyclosporine with best supportive care: SAKK 33/99. [Abstract] Blood 110 (11): A-1461, 2007."
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "Response rate at month 3, time to response, quality and duration of response, and proportions of relapse/progression in responders", 
                "safety_issue": "No", 
                "time_frame": "2 and 5 years after first response"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 and 5 years"
            }, 
            {
                "measure": "Leukemia-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 and 5 years"
            }, 
            {
                "measure": "Transformation-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 and 5 years"
            }
        ], 
        "source": "Swiss Group for Clinical Cancer Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Swiss Group for Clinical Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Universitaetsspital-Basel": "47.557 7.593"
    }
}